

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]

Final Stakeholder List

Provisional Consultees Provisional Commentators (no right to	
riovisioliai Colisuitees	Provisional Commentators (no right to
Company	submit or appeal)
CompanyDurvalumab (AstraZeneca)	GeneralAll Wales Therapeutics and Toxicology Centre
 Patient/carer groups Action Bladder Cancer UK Black Health Agency for Equality Bladder and Bowel Community Bladder and Bowel UK Cancer 52 Cancer Black Care Fight Bladder Cancer Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care 	 Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health – Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Welsh Government
 Healthcare professional groups Association of Cancer Physicians British Association of Urological Nurses British Association of Urological Surgeons British Geriatrics Society British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society British Society of Urogenital Radiology British Society of Urogynaecology British Uro-Oncology Group 	 Comparator companies Bristol Myers Squibb (nivolumab) Hospira UK (cisplatin, gemcitabine) Ranbaxy UK (Sun Pharma) (gemcitabine) Sandoz (cisplatin) Synchrony Pharma (CNX Therapeutics) (gemcitabine) Relevant research groups Cochrane Urology Genomics England Institute of Cancer Research

Final stakeholder list for the evaluation of durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Cancer Research UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Urology Foundation 	 MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees


Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]

Issue date: April 2025



Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.